<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00283556</url>
  </required_header>
  <id_info>
    <org_study_id>1068114</org_study_id>
    <secondary_id>44OE-ONC-0020-3</secondary_id>
    <nct_id>NCT00283556</nct_id>
  </id_info>
  <brief_title>High Dose Camptothecin-11 (CPT-11) in Recurrent Unresectable Malignant Glioma</brief_title>
  <official_title>Phase I/II Study of High Dose Irinotecan (Camptosar, CPT-11) in Patients With Recurrent Unresectable Malignant Glioma on Steroids/Anti-epileptics</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Kentuckiana Cancer Institute</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Kentuckiana Cancer Institute</source>
  <brief_summary>
    <textblock>
      The purpose of this study is to compare the response to treatment and side effects associated
      with high dose irinotecan in patients with recurrent brain tumors.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a phase I/II study of high dose irinotecan in patients with recurrent unresectable
      malignant glioma on steroids/anti-epileptics. The purpose is to compare the response to
      treatment and side effects associated with high dose irinotecan in patients with recurrent
      brain tumors.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>August 2001</start_date>
  <completion_date type="Actual">December 2008</completion_date>
  <primary_completion_date type="Actual">December 2008</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The purpose of this study is to compare the response to treatment and side effects associated with high dose irinotecan in patients with recurrent brain tumors.</measure>
    <time_frame>2008</time_frame>
  </primary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">30</enrollment>
  <condition>Malignant Glioma</condition>
  <arm_group>
    <arm_group_label>Cohort #1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Cohort #1--Irinotecan 750 mg/m2 IV over 90 minutes every (Q) 3 weeks x 15 patients.
Additional increments of 50 mg/m2 for subsequent cohorts until MTD is reached.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort #2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Cohort #2--Irinotecan 500 mg/m2 IV over 90 minutes Q 2 weeks x 3 patients.
Additional increments of 50 mg/m2 for subsequent cohorts until MTD is reached.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort #3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Cohort #3--Irinotecan 600 mg/m2 IV over 90 minutes Q 2 weeks x 3 patients.
Additional increments of 50 mg/m2 for subsequent cohorts until MTD is reached.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Irinotecan (Camptosar, CPT-11)</intervention_name>
    <description>Cohort #1--Irinotecan 750 mg/m2 IV over 90 minutes Q 3 weeks x 15 patients; Cohort #2--Irinotecan 500 mg/m2 IV over 90 minutes Q 2 weeks x 3 patients; Cohort #3--Irinotecan 600 mg/m2 IV over 90 minutes Q 2 weeks x 3 patients.
Additional increments of 50 mg/m2 for subsequent cohorts until MTD is reached.</description>
    <arm_group_label>Cohort #1</arm_group_label>
    <arm_group_label>Cohort #2</arm_group_label>
    <arm_group_label>Cohort #3</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  recurrent, unresectable primary CNS neoplasm per MRI

          -  ECOG status of 2 or less

          -  no prior therapy with camptothecans

          -  on an enzyme-inducing antiepileptic
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Renato V. LaRocca, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Director</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Kentuckiana Cancer Institute</name>
      <address>
        <city>Louisville</city>
        <state>Kentucky</state>
        <zip>40202</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>January 2010</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 26, 2006</study_first_submitted>
  <study_first_submitted_qc>January 26, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 30, 2006</study_first_posted>
  <last_update_submitted>January 18, 2010</last_update_submitted>
  <last_update_submitted_qc>January 18, 2010</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 20, 2010</last_update_posted>
  <keyword>High Dose Irinotecan</keyword>
  <keyword>CPT-11</keyword>
  <keyword>Camptosar</keyword>
  <keyword>Malignant Glioma</keyword>
  <keyword>Unresectable</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Glioma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Irinotecan</mesh_term>
    <mesh_term>Camptothecin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

